Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)-Reference-Cited by-同舟云学术

Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)

Published:2021-07-02 Issue:2 Volume:63 Page:240-247
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Cerci Juliano J.,Fanti Stefano,Lobato Enrique E.,Kunikowska Jolanta,Alonso Omar,Medina Sevastian,Novruzov Fuad,Lengana Thabo,Granados Carlos,Kumar Rakesh,Rangarajan Venkatesh,Al-Ibraheem Akram,Hourani Mukbil,Ali Nor S.,Ahmad Azra,Keidar Zohar,Küçük Ozlem,Elboga Umut,Bogoni Mateos,Paez Diana

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference46 articles.

1. Ferlay JEM Lam F Colombet M .Global cancer observatory: cancer tomorrow. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr/today/data/factsheets/cancers/40-All-cancers-excluding-non-melanoma-skin-cancer-fact-sheet.pdf. Accessed December 21, 2021.

2. Epidemiology of Prostate Cancer

3. Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning;Gupta;Int J Radiat Oncol Biol Phys.,2017

4. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer;Meredith;BJU Int.,2016

5. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluación de la tasa de detección de la recidiva local y de cuerpo completo mediante la valoración integrada de la PET/RM con [18F]F-PSMA-1007 de pacientes con cáncer de próstata tratados con prostatectomía con recidiva bioquímica muy baja (< 0,5 ng/ml). Implicaciones terapéuticas;Revista Española de Medicina Nuclear e Imagen Molecular;2024-09

2. To evaluate the detection rate of local and whole-body recurrence by integrated [18F]F-PSMA-1007 PET/MR assessment of prostate cancer patients treated with prostatectomy with very low biochemical recurrence (<0.5 ng/ml). Therapeutic implications;Revista Española de Medicina Nuclear e Imagen Molecular (English Edition);2024-09

3. Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study;Advances in Radiation Oncology;2024-08

4. ⁶¹Cu-PSMA–Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging;Journal of Nuclear Medicine;2024-07-18

5. Navigating The Prostate Cancer Frontier: A Bibliometric and Altmetric Analysis of [225Ac]Ac-PSMA Therapy;Seminars in Nuclear Medicine;2024-07